ReviewDiscover oncology2025
Ubiquitin-specific proteases as key regulators in the malignant progression and therapy resistance of colorectal cancer: current insights and future perspectives.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
As a member of the DUBs (deubiquitinating enzymes) family, USPs (ubiquitin-specific peptidases) play a crucial regulatory role in the occurrence and progression of various malignancies. This review summarizes the current research on USPs in colorectal cancer, with a focus on the involvement of different USPs as either oncogenes or tumor suppressor genes in regulating the malignant progression of colorectal cancer. We discuss in detail the regulatory role of USPs in the process of drug resistance in tumors, the signaling pathways regulated by USPs, the correlation between different USP expression levels and early diagnosis and prognostic evaluation, as well as the latest research developments in USP inhibitors. Mechanistically, USPs regulate key proteins in several signaling pathways, including Wnt, P53, and PI3K/Akt/mTOR, highlighting their significant role in the malignant progression of colorectal cancer. Finally, we further discuss the functional and mechanistic differences among various USPs, the challenges faced in developing USP inhibitors, and prospects for future research directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.